Product image of Meflynate Xl (Methylphenidate Hydrochloride) supplied by GNH India

Meflynate Xl

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Meflynate Xl (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride, the active ingredient in Meflynate Xl, is a central nervous system stimulant presented as an oral formulation for oral use. It is prescribed to manage symptoms of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH India supplies Meflynate Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for regulated medicines. Our network ensures timely delivery across Europe, Asia, Africa and the Americas.

Manufacturer / TM Owner

Flynn Pharma Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylphenidate hydrochloride is a central nervous system stimulant used in the management of neurodevelopmental and sleep‑wake disorders.

  • Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves concentration, reduces hyperactivity and impulsivity.
  • Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and executive function.
  • Narcolepsy: decreases daytime sleepiness and improves wakefulness.

How It Works

  • Methylphenidate hydrochloride blocks the reuptake of dopamine and norepinephrine at presynaptic neuronal membranes, increasing their extracellular concentrations in the central nervous system. The elevated catecholamine levels enhance neurotransmission in the prefrontal cortex and related pathways, which modulates attention, impulse control and arousal. These actions result in improved signal‑to‑noise ratio in cortical circuits responsible for executive functions, thereby reducing core symptoms of ADHD and promoting wakefulness in narcoleptic patients.

Side Effects

Methylphenidate hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Appetite loss: reduced hunger leading to weight loss.
  • Headache: mild to moderate cranial pain.
  • Stomach upset: nausea, abdominal discomfort.

Serious or Rare Side Effects

  • Cardiovascular events: chest pain, hypertension, tachycardia.
  • Psychiatric symptoms: new or worsening anxiety, agitation, psychosis.
  • Allergic reactions: rash, urticaria, anaphylaxis.

Precautions & Warnings

When prescribing methylphenidate hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

  • Assess cardiovascular health: evaluate blood pressure and heart rate before initiation.
  • Monitor growth in children: track height and weight regularly.
  • Review psychiatric history: be cautious in patients with anxiety, bipolar disorder or psychosis.
  • Avoid use with MAO inhibitors: ensure a washout period of at least 14 days.
  • Educate about misuse: inform patients of abuse potential and proper storage.
  • Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Avoid Interactions

Methylphenidate hydrochloride can interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis.
  • Tricyclic antidepressants: increased risk of cardiovascular side effects.
  • Antihypertensive agents: may reduce blood pressure control.

Moderate Interactions (Monitor Closely)

  • Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin levels, watch for serotonin syndrome.
  • CYP2D6 inhibitors (e.g., fluoxetine): can raise methylphenidate plasma concentrations.
  • Antacids: may alter absorption, monitor therapeutic response.

Frequently Asked Questions

Meflynate Xl contains methylphenidate hydrochloride and is prescribed to treat attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults, as well as to reduce excessive daytime sleepiness in patients with narcolepsy.

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the brain, raising their levels at synapses. The increased catecholamine activity enhances signaling in the prefrontal cortex, which improves attention, impulse control and wakefulness.

The appropriate dose of Meflynate Xl is individualized by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. No fixed dosing regimen is provided here.

Safety data for methylphenidate in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks and discuss any concerns with a qualified medical professional before use.

To request Meflynate Xl, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meflynate Xl (methylphenidate) is a non‑amphetamine stimulant, whereas alternatives such as amphetamine‑based products act on similar pathways but have different pharmacokinetic profiles. Choice of therapy depends on efficacy, side‑effect tolerance, comorbid conditions and physician preference.

Store Meflynate Xl at ambient temperature, preferably below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Meflynate Xl is taken orally. The tablet should be swallowed whole with a glass of water, preferably in the morning and, if prescribed, a second dose early in the afternoon. It should be taken exactly as directed by the prescriber.

Serious risks include cardiovascular events such as hypertension, tachycardia or chest pain, as well as psychiatric effects like new or worsening anxiety, agitation, or psychosis. Rarely, severe allergic reactions can occur. Patients should be monitored closely for these events.

Meflynate Xl is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, or patients with severe cardiovascular disorders, uncontrolled hypertension, or certain psychiatric conditions without specialist supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT